Lv21
194 积分 2024-04-17 加入
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
3小时前
已完结
Clinical research progress on BRAF V600E-mutant advanced colorectal cancer
3小时前
已完结
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial
7天前
已完结
The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
7天前
已完结
Immune suppression and reversal of the suppressive tumor microenvironment
9天前
已完结
Diagnosis and Treatment of Metastatic Colorectal Cancer
14天前
已完结
[Consensus of Chinese experts on clinical detection of molecular markers of colorectal cancer]
14天前
已完结
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer
17天前
已完结
Class 1, 2, and 3BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
18天前
已完结
Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials
21天前
已完结
皖公网安备34019202002308
